CUDC-907: Additional Phase I data

Data from 10 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in an open-label, dose-escalation, U.S. Phase I trial showed that CUDC-907

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE